MedTrace Logo

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

NCT02534038 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.

Conditions

  • Disinhibition Syndrome

Interventions

DRUG

AVP-786

d6-DM/Q

DRUG

Placebo

matching placebo

Sponsors & Collaborators

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-01
Primary Completion
2017-10-03
Completion
2017-10-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02534038 on ClinicalTrials.gov